# Clinical Lung Cancer

**Type:** Journals  
**Canonical URL:** https://scholariq.org/journals/clinical-lung-cancer/

## Facts

| Field | Value |
| --- | --- |
| APC (USD) | 3,110 |
| Citations | 61,786 |
| h-index | 92 |
| Homepage | https://www.sciencedirect.com/journal/clinical-lung-cancer |
| Open Access | false |
| ISSN-L | 1525-7304 |
| ISSNs | 1525-7304,1938-0690 |
| OpenAlex ID | https://openalex.org/S32518486 |
| Publisher | Elsevier BV |
| Works | 3,217 |

## Journal papers

Showing 12 of 18.

- [Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients](https://scholariq.org/papers/correlations-between-the-immune-related-adverse-events-spectrum-and-efficacy-of/)
- [Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small-cell Lung Cancer](https://scholariq.org/papers/soluble-programmed-cell-death-ligand-1-as-a-novel-biomarker-for-nivolumab/)
- [Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non–Small-Cell Lung Cancer](https://scholariq.org/papers/reliability-of-small-biopsy-samples-compared-with-resected-specimens-for-the/)
- [Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer](https://scholariq.org/papers/evidence-of-ntrk1-fusion-as-resistance-mechanism-to-egfr-tki-in-egfr-nsclc/)
- [Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes](https://scholariq.org/papers/immune-related-adverse-events-of-pembrolizumab-in-a-large-real-world-cohort-of/)
- [Toxicity of Targeted Therapy in Non–Small-Cell Lung Cancer Management](https://scholariq.org/papers/toxicity-of-targeted-therapy-in-non-small-cell-lung-cancer-management/)
- [The Impact of Beta Blockers on Survival Outcomes in Patients With Non–small-cell Lung Cancer Treated With Immune Checkpoint Inhibitors](https://scholariq.org/papers/the-impact-of-beta-blockers-on-survival-outcomes-in-patients-with-non-small-cell/)
- [Immune Microenvironment Differences Between Squamous and Non-squamous Non–small-cell Lung Cancer and Their Influence on the Prognosis](https://scholariq.org/papers/immune-microenvironment-differences-between-squamous-and-non-squamous-non-small/)
- [High-resolution Computed Tomography Features Distinguishing Benign and Malignant Lesions Manifesting as Persistent Solitary Subsolid Nodules](https://scholariq.org/papers/high-resolution-computed-tomography-features-distinguishing-benign-and-malignant/)
- [Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non–Small-cell Lung Cancer](https://scholariq.org/papers/epidermal-growth-factor-receptor-tyrosine-kinase-inhibitor-sensitive-exon-19/)
- [Progression-Free and Overall Survival of Patients With ALK Rearrangement–Positive Non–Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib](https://scholariq.org/papers/progression-free-and-overall-survival-of-patients-with-alk-rearrangement/)
- [Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non–Small-Cell Lung Cancer: Analysis and Literature Review](https://scholariq.org/papers/anaplastic-lymphoma-kinase-alk-kinase-domain-mutation-following-alk-inhibitor-s/)

## Journal top topics

Showing 8 of 25.

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Radiomics and Machine Learning in Medical Imaging](https://scholariq.org/topics/radiomics-and-machine-learning-in-medical-imaging/)
- [Diverse Scientific and Economic Studies](https://scholariq.org/topics/diverse-scientific-and-economic-studies/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.